Update on the appropriate staging evaluation for newly diagnosed prostate cancer

Journal of Urology

Volumn 158, Issue 3, 1997, Pages 687-698

  O'Dowd, Gerard J ^a   Veltri, Robert W ^b   Orozco, Roberto ^b   Miller, M Craig ^b   Oesterling, Joseph E ^b  

^a UroCor Incorporated   (United States)

^b NONE

Author keywords

Algorithms; Decision support techniques; Neoplasm staging; Prostatic neoplasms

Indexed keywords

BONE METASTASIS; CANCER STAGING; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHADENECTOMY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SCORING SYSTEM;

EID: 0030791567     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64295-2     Document Type: Review

References (140)

1. Catalona, W. J., Smith, D. S., Ratcliff, T. L., Dodds, K. M., Coplen, D. E., Yaran, J. J., Petros, J. A. and Andriole, G. L.: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. New Engl. J. Med., 324: 1156, 1991.
2. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H.: Screening for prostatic carcinoma with Prostate Specific Antigen. J. Urol., 147: 841, 1992.
3. Catalona, W. J., Smith, D. S., Ratliff, T. L. and Basler, J. N.: Detection of organ confined prostate cancers is increased through PSA based screening. J.A.M.A., 270: 948, 1993.
4. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., Mac Farlane, M. T. and Southwick, P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
5. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N. and Lowe, B. A.: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845, 1993.
6. Androile, G. L., Smith, D. S., Rao, G., Goodnough, L. and Catalona, W. J.: Early complications of contemporary anatomical radical retropubic prostatectomy. J. Urol., 152: 1858, 1994.
7. Catalona, W. J. and Smith, D. S.: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
8. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. E. and Wein, A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131, 1995.
9. Epstein, J. I., Walsh, P. C. and Brendler, C. B.: Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1a and T1b) and on needle biopsy (stage T1c). J. Urol., 152: 1721, 1994.
10. Hammerer, P., Huland, H. and Sparenberg, A.: Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur. Urol., 22: 281, 1992.
11. Litwiller, S. E., Djavan, B., Klopukh, B. V., Richier, J. C. and Roehrborn, C. G.: Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Urology, 45: 813, 1995.
12. Mettlin, C., Murphy, G. P., Lee, F., Littrup, P. J., Chesley, A., Babaian, R., Badalament, R., Kane, R. A. and Mostofi, F. K.: Investigators of the American Cancer Society-National prostate cancer detection project. Characteristics of prostate cancer detected in the American cancer detection project. J. Urol., 152: 1737, 1994.
13. Murphy, G. P., Mettlin, C., Menck, H., Winchester, D. P. and Davidson, A. M.: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons commission on cancer. J. Urol., 152: 1817, 1994.
14. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C. and Scardino, P. T.: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J. Urol., 152: 1843, 1994.
15. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1993.
16. Paulson, D. F.: Impact of radical prostatectomy in the management of clinically localized disease. J. Urol., 152: 1826, 1994.
17. Peller, P. A., Young, D. C., Marmaduke, D. P., Marsh, W. L. and Badalament, R. A.: Sextant Prostate Biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer, 75: 530, 1995.
18. Ravery, V., Boccon-Gibod, L. A., Dauge-Geffroy, M. C., Billebaud, T., Delmas, V., Meulemans, A., Toublanc, M. and Boccon-Gibod, L.: Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology, 44: 371, 1994.
19. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., 152: 1821, 1994.
20. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831, 1994.
21. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., 152: 1850, 1994.
22. Oesterling, J. E.: Using PSA to eliminate the staging radio nuclide bone scan. Significant economic implications. Urol. Clin. N. Amer., 20: 705, 1993.
23. Chybowski, F. M., Larson-Keeler, J. J., Bergstralh, E. J. and Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145: 313, 1991.
24. Oesterling, J. E., Martin, S. K., Bergstralh, E. J. and Lowe, F. C.: The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269: 57, 1993.
25. Wolf, J. S., Jr., Cher, M., Dallera, M., Presti, J. C., Jr., Hricak, H. and Carroll, P. R.: The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastasis before radical prostatectomy. J. Urol., 153: 993, 1995.
26. Koch, M. O., Smith, J. A., Hodge, E. M. and Brandell, R. A.: Prospective development of a cost-efficient program for radical retropubic prostatectomy. Urology, 44: 311, 1994.
27. Licht, M. R. and Klein, E. A.: Early hospital discharge after radical retropubic prostatectomy: Impact on cost and complication rate. Urology, 44: 700, 1994.
28. Parker, S. L., Tong, T. O., Bolden, S. and Wingo, P. A.: Cancer statistics 1996. CA, 65: 5, 1996.
29. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
30. Epstein, J. I., Carmichael, M. J., Pizov, G. and Walsh, P. C.: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J. Urol., 150: 135, 1993.
31. Whitmore, W. F., Jr.: Hormone therapy in prostate cancer. Amer. J. Med., 21: 697, 1956.
32. Jewett, H. J.: The present status of radical prostatectomy for stages A and B prostatic cancer. Urol. Clin. N. Amer., 2: 105 1975.
33. Wallace, D. M., Chisholm, G. D. and Hendry, W. F.: T.N.M. classification for urological tumors (U.I.C.C.) - 1974. Brit. J. Urol., 47: 1, 1975.
34. American Joint Committee on Cancer: Manual for Staging of Cancer, 3rd ed. Philadelphia: J. B. Lippincott Co., pp. 1, 1988.
35. American Joint Committee on Cancer: Manual for Staging of Cancer, 2nd ed. Philadelphia: J. B. Lippincott Co., pp. 159-164, 1983.
36. Beahrs, O. H., Henson, D. E., Hutter, R. V. P. and Kennedy, B. J.: Genitourinary Cancers: American Joint Committee on Cancer: Manual for Staging of Cancer, 4th ed. Philadelphia: J. B. Lippincott Co., Part II, pp. 181-212, 1992.
37. Sobin, L. H., Hermanck, P. and Hutter, R. V. P.: TMN classification of malignant tumors, a comparison between the new (1987) and old editions. Cancer, 61: 2310, 1988.
38. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
39. Graham, S. D., Jr., Bostwick, D. G., Hoisaeter, A., Abrahamsson, P., Algaba, F., di Sant'Agnese, A., Mostofi, F. K. and Napalkol, P.: Report of the committee on staging and pathology. Cancer, suppl., 70: 359, 1992.
40. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
41. Oesterling, J. E.: Molecular PSA: The next frontier in PSA screening. Contemp. Urol., 8: 76, 1996.
42. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: clinicopathologic correlations. Cancer, 73: 104, 1994.
43. Vollmer, R. T.: Multivariate statistical analysis for pathologists. Part I, The logistic model. Amer. J. Clin. Path., 105: 115, 1996.
44. Badalament, R. A., Miller, M. C., Peller, P. A., Young, D. C., Bahn, D. K., Kochie, P., O'Dowd, G. J. and Veltri, R. W.: An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with PSA level. J. Urol., 156: 1375, 1996.
45. Bostwick, D. G., Qian, J., Bergstralh, E., Dundore, P., Dugan, J., Myers, R. P. and Oesterling, J. E.: Prediction of Capsular Perforation and Seminal Vesicle Invasion in Prostate Cancer. J. Urol., 155: 1361, 1996.
46. Narayan, P., Gajendrau, V., Taylor, S. K., Tewari, A., Presti, J. C., Jr., Leidich, R., Lo, R., Palmer, K., Shinohara, K. and Spaulding, J. T.: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology, 46: 205, 1995.
47. Bluestein, D. L., Bostwick, D. G., Bergstralh, E. J. and Oesterling, J. E.: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol., 151: 1315, 1994.
48. Terris, M. K., Hanly, D. J., Johnstone, I. M., McNeal, J. E. and Stamey, T. A.: Prediction of prostate cancer volume using prostate specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology, 45: 75, 1995.
49. Rifkin, M. D., Zerhouni, E. A., Gatsonis, C. A., Quint, L. E., Panshter, D. M., Epstein, J. I., Hamper, V., Walsh, P. C. and McNeil, B. J.: Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi institutional cooperative trial. New Engl. J. Med., 323: 621, 1990.
50. Tempany, C. M., Zhou, X., Zerhouni, E. A., Rifkin, M. D., Quint, L. E., Picollo, C. W., Ellis, J. H. and McNeil, B. J.: Staging of prostate cancer: results of radiology diagnostic oncology group project comparison of three different MR imaging techniques. Radiology, 92: 47, 1994.
51. Bastacky, S. I., Walsh, P. C. and Epstein, J. I.: Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Amer. J. Surg. Path., 17: 336, 1993.
52. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
53. Noldus, J. and Stamey, T. A.: Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng/ml or less. J. Urol., 155: 441, 1996.
54. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-Detected (Clinical Stage T1c or B0) Prostate Cancer. Urol. Clin. N. Amer., 20: 687, 1993.
55. Gutman, G. A. and Gutman, E. B.: Acid phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest., 17: 473, 1938.
56. Huggins, C., Stevens, R. E., Jr. and Hodges, C. V.: Studies on prostatic cancer; effect of castration on advanced carcinoma of prostate gland. Arch. Surg., 43: 209, 1941.
57. Heller, J. E.: Prostatic acid phosphatase: its current clinical status. J. Urol., 37: 1091, 1991.
58. Foti, A. G., Herschman, H. and Cooper, J. F.: A solid phase radioimmunoassay for human prostatic acid phosphatase. Cancer Res., 35: 2446, 1975.
59. Whitesel, J. A., Donohue, R. E., Mani, J. H., Mohr, S., Scanavino, D. J., Augspurger, R. R., Biber, R. J., Fauver, H. E., Wettlaufer, J. N. and Pfister, R. R.: Acid phosphatase. Its influence on the management of carcinoma of the prostate. J. Urol., 131: 70, 1984.
60. Bahnson, R. R. and Catalona, W. J.: Adverse implications of acid phosphatase levels in the upper range of normal. J. Urol., 137: 427, 1987.
61. Oesterling, J. E., Brendler, C. B., Epstein, J. I., Kimball, A. W., Jr. and Walsh, P. C.: Correlation of clinical stage, serum prostate acid phosphatase and preoperative Gleason Grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol 138: 92 1987.
62. Ahman, F. R. and Schifman, R. B.: Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. J. Urol., 137: 431, 1987.
63. Morote Robles J., Ruibal Morell, A., Pulou Redorta, J., deToress Mateos, J. A. and Soler Rosello, A.: Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur. Urol., 14: 360, 1988.
64. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med. 317: 909, 1987.
65. Burnett, A. L., Chan, D. W., Brendler, C. B. and Walsh, P. C.: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J. Urol., 148: 1832, 1992.
66. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperation and post operative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
67. 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
68. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
69. McCormack, R. T., Rittenhouse, H. G., Finlay, J. A., Sokoloff, R. L., Wang, T. J., Wolfert, R. L., Lilja, H. and Oesterling, J. E.: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology, 45: 729, 1995.
70. 1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
71. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.
72. Oesterling, J. E., Jacobsen, S. J., Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P. A., Stenman, U. H., Dowell, B., Lövgren, T. and Lilja, H.: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 154: 1090, 1995.
73. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I. and Oesterling, J. E.: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume, and benign hyperplasia. J. Urol., 143: 747, 1990.
74. Ercole, C. J., Lange, P. H., Methisen, M., Chiou, R. K., Reddy, P. K. and Vessella, R. L.: Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostate cancer. J. Urol., 138: 1181, 1987.
75. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
76. Rainwater, L. M., Morgan, W. R., Klee, G. G. and Zincke, H.: Prostate specific antigen testing in untreated and treated prostate adenocarcinoma. Mayo Clin. Proc., 65: 1118, 1990.
77. Haapiainen, R. K., Perni, E. J., Rannikko, S. A. S., Voutilainen, P. E., Liewendahl, K., Stenman, U. H. and Alfthan, O. S.: Prostate tumour markers as an aid in staging of prostate cancer. Brit. J. Urol., 65: 264, 1990.
78. Ruckle, H. C., Kleer, G. C. and Oesterling, J. E.: Prostate specific antigen: Concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin. Proc., 69: 69, 1994.
79. Kleer, E., Larson-Keller, J. J., Zincke, H. and Oesterling, J. E.: Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology, 41: 207, 1994.
80. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol., 142: 71, 1989.
81. Hammerer, P. and Huland, H.: Systematic sextant biopsies of 651 patients referred for prostate evaluation. J. Urol., 151: 99, 1994.
82. Dyke, C. H., Toi, A. and Sweet, J. M.: Value of random US-guided transrectal prostate biopsy. Radiology, 176: 345, 1990.
83. Billebaud, T., Villers, A., Astier, L., Boccon-Gibod, L., Darge, M. C., Sibert, A., Baron, J. C. and Delmas, V.: Advantage of systematic random ultrasound guided biopsies measurement of serum prostate specific antigen levels and determination of prostate volume in the early diagnosis of prostate cancer. Eur. Urol., 21: 6, 1992.
84. Daniels, G. F., McNeal, J. E. and Stamey, T. A.: Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. J. Urol., 147: 870, 1992.
85. Stamey, T. A.: Making the most out of six systematic sextant biopsies. Urology, 45: 2, 1995.
86. Dietrick, D. D., McNeal, J. E. and Stamey, T. A.: Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987, 1995.
87. Voges, G. E., McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer, 69: 520, 1990.
88. Stamey, T. A., Villers, A. A., McNeal, J. E., Link, P. C. and Frieha, F. S.: Positive surgical margins at radical prostatectomy importance of apical dissection. J. Urol., 143: 1166, 1990.
89. Huland, H., Hubner, D. and Henke, R. P.: Systematic biopsies and digital rectal examination to identify the nerve sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2 NO prostatic carcinoma. Urology, 44: 271, 1994.
90. Gleason, D. F.: Classification of prostatic carcinomas. Cancer Chemother. Rep., 50: 125, 1966.
91. Bailar, J. C., III, Melliger, G. Y. and Gleason, D. F.: Survival rates of patients with prostatic cancer, tumor stage, and differentiation-a preliminary report. Cancer Chemother. Rep., 50: 129, 1966.
92. Gleason, D. F. and Mellinger, G. T.: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58, 1974.
93. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum prostate specific antigen after anatomic radical prostatectomy: The Johns Hopkins Experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
94. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
95. Partin, A. W., Piantadosi, S., Sanda, M. G., Epstein, J. I., Marshall, F. F., Mohler, J. L., Brendler, C. B., Walsh, P. C. and Simons, J. W.: Selection of men at high risk for disease recurrence for experimental adjutant therapy following radical prostatectomy. Urology, 45: 831, 1992.
96. Carmichael, M. J., Veltri, R. W., Partin, A. W., Miller, M. C., Walsh, P. C. and Epstein, J. I.: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J. Urol., 153: 1015, 1995.
97. Zeitman, A. L., Edelstein, R. A., Coen, J. J., Babayan, R. K. and Krane, R. J.: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828, 1994.
98. Sands, E. M., Zagars, G. K., Pollock, A. and Von Eschenbach, A. C.: Serum prostate specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology, 44: 215, 1994.
99. Irwin, M. B. and Trapasso, J. C.: Identification of insignificant prostate cancers: Analysis of preoperative parameters. Urology, 44: 862, 1994.
100. Blackwell, K. L., Bostwick, D. G., Myers, R. P., Zinke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
101. Partin, A. W., Coffey, D. S., Weinstein, R. S. and Gardner, W. A., Jr.: Pathology and Pathobiology of the Urinary Bladder and Prostate. Baltimore: Williams & Wilkens, pp. 198-218, 1992.
102. Miller, G. J. and Cygan, J. M.: Morphology of prostate cancer the effects of multifocality on histological grade, tumor volume, and capsular penetration. J. Urol., 152: 1709, 1994.
103. Epstein, J. I.: The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Cancer, 78: 350, 1996.
104. Vallencien, G., Bocherean, Ghislain, Wetzel, O., Bretheau, D., Prapotnich, D. and Bougaran, J.: Influence of preoperative positive seminal vesicle biopsy on the staging of prostate cancer. J. Urol., 152: 1152, 1994.
105. Allepuz Losa, C. A. A., Sanz Velez, J. I., Gil Sanz, M. J., Plaza Mas, L. and Rioja Sanz L. A.: Seminal vesicle biopsy in prostate cancer staging. J. Urol., 154: 1407, 1995.
106. Terris, M. K., McNeal, J. E., Freiha, F. S. and Stamey, T. A.: Efficiency of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J. Urol., 149: 1035, 1993.
107. Pandy, P., Fowler, J. E., Seaver, L. E., Feliz, T. P. and Brooks, J. P.: Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer. J. Urol., 154: 1798, 1995.
108. Stone, N. N., Stock, R. G. and Unger, P.: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J. Urol., 154: 1392, 1995.
109. Chelsky, M. J., Schnall, M. D., Seidman, E. J. and Pollack, H. M.: Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J. Urol., 150: 391, 1993.
110. Gerber, G. and Chodak, G. W.: Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology, 37: 418, 1991.
111. Schaffer, D. L. and Pendergrass, H. P.: Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology, 121: 431, 1976.
112. Terris, M. K., Klonecke, A. S., McDouqall, I. R. and Stamey, T. A.: Utilization of bone scans in conjunction with prostate specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 32: 1713, 1991.
113. Lentle, B. C., McGowan, D. G. and Dierich, H.: Technetium-99m polyphosphate bone scanning in carcinoma of the prostate. Brit. J. Urol., 46: 543, 1994.
114. Catalona, W. J. and Biggs, S. W.: Nerve sparing radical prostatectomy: evaluation of results after 250 patients. J. Urol., 143: 538, 1990.
115. Danella, J. F., de Kernion, J. B., Smith, R. B. and Steckel, J.: The contemporary incidence of lymph node metastases in prostate cancer: Implications for laproscopic lymph node dissection. J. Urol., 149: 1488, 1993.
116. Petros, J. A. and Catalona, W. J.: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol., 147: 1574 1992.
117. Winfield, H. N.: Laparoscopy in urology. Urol. Times 21: 6 1993.
118. Wolfe, J. S., Jr., Shinohara, K., Kerlikowske, K. M., Narayan, P., Stoller, M. L. and Carroll, P. R.: Selection of patients for laparoscopic pelvic lymphadenectomy prior to radical prostatectomy: a decision analysis. Urology, 42: 680, 1993.
119. Flanigan, R. C., Mohler, J. L., King, C. T., Atwell, J. R., Umer, M. A., Loh, F. K. and McRoberts, J. W.: Preoperative lymph node evaluation in prostatic cancer patients who are surgical candidates: the rate of lymphangiography and computerized tomography scanning with directed fine needle aspiration. J. Urol., 134: 1, 1985.
120. Oyen, R. H., Van Poppel, H. P., Ameye, F. E., Van de Voorde, W. A., Baert, A. L. and Baert, L. V.: Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine needle aspiration biopsy: prospective study of 285 patients. Radiology, 190: 315, 1994.
121. Correa, R. J., Jr., Kidd, C. R., Burnett, L., Brannen, G. E., Gibbons, R. P. and Cumming, K. B.: Percutaneous pelvic lymph node aspiration in carcinoma of the prostate. J. Urol., 126: 190, 1981.
122. von Eschenbach, A. C. and Zornoza, J.: Fine needle percutaneous biopsy: a useful evaluation of lymph node metastases from prostate cancer. Urology, 20: 589, 1982.
123. Wajsman, Z., Gamarra, M., Park, J. J., Beckley, S. and Pontes, J. E.: Transabdominal fine needle aspiration of retroperitoneal lymph nodes in staging of genetourinary tract cancer (correlation with lymphography and lymph node dissection findings). J. Urol., 128: 1238, 1982.
124. Piscioli, F., Scappini, P. and Luciani, L.: Aspiration cytology in the staging of urologic cancer. Cancer, 56: 1173, 1985.
125. Cochand-Priollet, B., Roger, B. and Boccon-Gibod, I., Ferrand, J., Favre, B. and Bleny, M.: Retroperitoneal lymph node aspiration biopsy in staging of pelvic cancer: a cytological study of 228 consecutive cases. Diag. Cytopath., 3: 102, 1987.
126. Chagnon, S., Cochland-Priollet, B., Gzaleil, M., Jacquenard, P., Roger, B., Boccon-Gibod, L. and Blery, M.: Pelvic cancers staging of 139 cases with lymphography and fine needle aspiration biopsy. Radiology, 173: 103, 1989.
127. Fowler, J. E., Jr., Torgerson, L., McLeod, D. G. and Stutzman, R. E.: Radical prostatectomy with pelvic lymphadenectomy: observations on the accuracy of staging with lymph node frozen sections. J. Urol., 126: 618, 1981.
128. Steiner, M. S. and Marshall, F. F.: Mini laparotomy staging pelvic lymphadenectomy (menilap). Alternative to standard and laproscopic pelvic lymphadenectomy. Urology 41: 201 1993.
129. Catalona, W. J. and Stein, A. J.: Accuracy of frozen section detection of lymph node metastases in prostatic carcinoma J. Urol., 127: 460, 1982.
130. Kramolowsky, E. V., Narayana, A. S., Platz, C. E. and Loening, S. A.: The frozen section in lymphadenectomy for carcinoma of the prostate. J. Urol., 131: 899, 1984.
131. Sadlowski, R. W., Donahue, D. J., Richman, A. V., Sharpe, J. R. and Finney, R. P.: Accuracy of frozen section diagnosis in pelvic lymph node staging biopsies for adenocarcinoma of the prostate. J. Urol., 129: 324, 1983.
132. Brendler, C. B., Cleeve, L. K., Anderson, E. E. and Paulson, D. F.: Staging pelvic lymphadenectomy for carcinoma of the prostate: risk versus benefits. J. Urol., 124: 849, 1980.
133. Lieskovsky, G., Skinner, D. G. and Weisenberger, T.: Pelvic lymphadenectomy in the management of carcinoma of the prostate. J. Urol., 124: 635, 1980.
134. Grossman, I. C., Carpiniello, V., Greenberg, Malloy, T. R. and Wein, A. J.: Staging pelvic lymphadenectomy for carcinoma of the prostate: review of 91 cases. J. Urol., 124: 632, 1980.
135. Paul, D. B., Loening, S. A., Narayana, A. S. and Culp, D. A.: Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate. J. Urol., 129: 1141, 1983.
136. Livne, P. M., Huben, R. P., Wolf, R. M. and Pontes, J. E.: Early complications of combined pelvic lymphadenectomy and radical prostatectomy versus lymphadenectomy alone. Prostate 8: 313, 1986.
137. McDowell, G. C., II, Johnson, J. W., Tenney, D. M. and Johnson, D. E.: Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases. Urology, 35: 476, 1990.
138. Winfield, H. N., See, W. A., Donovan, J. F., Godet, A., Farage, Y. M., Loening, S. A. and Williams, R. D.: Comparative effectiveness and safety of laparoscopic versus open pelvic lymph node dissection for cancer of prostate. J. Urol., part 2, 147(2): 244A, abstract 124, 1992.
139. Narayan, P., Fournier, G., Gajendran, V., Leidich, R., Lo, R., Wolf, J. S., Jr., Jacob, G., Nicolaisen, G., Palmer, K. and Freiha, F.: Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology, 44: 519, 1994.
140. Kerbl, K., Clayman, R. V., Petros, J. A., Chandhoke, P. S. and Gill, I. S.: Staging pelvic lymphadenectomy for prostate cancer: a comparison of laproscopic and open techniques. Urology, 150: 396, 1993.